daratumumab,lenalidomide,dexamethasone,carfilzomib
janssen
['congrat', 'master trial', 'mmsm']
the topic of dozens more #mmsm journal clubs to come - congrats et al on master trial at #eha23! mrd neg can be a middle point and not just an endpoint: better reflection of tumor biology. and our trials can better the demographics of the #mmsm pts we treat!! 
Asst Professor @UWMedicine @fredhutch. Goal: improve pt experience in myeloma #MMsm: ⬇️ dex! ⬆️ time at home! 📱-based wellness!

COI: https://t.co/3Uuojuio6R